<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A cohort of 76 patients with previous chemotherapy for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> received high-dose <z:chebi fb="0" ids="3423">carmustine</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi>-<z:chebi fb="0" ids="22601">arabinoside</z:chebi> and melphalan (BEAM) followed by autologous stem cell transplantation (ASCT) and was followed for relapse and development of leukemic complications </plain></SENT>
<SENT sid="1" pm="."><plain>Six patients, four with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and two with non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, developed leukemic complications, <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in four cases and overt <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in two </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> six showed an abnormal karyotype, in four of them highly characteristic of <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and therapy-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The cumulative risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> increased from 16 months after start of the primary chemotherapy for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and reached 17.3% (s.e </plain></SENT>
<SENT sid="4" pm="."><plain>8.5%) after 74 months </plain></SENT>
<SENT sid="5" pm="."><plain>If calculated from start of BEAM and ASCT, the cumulative risk increased as early as 4 months and reached 24.3% (s.e </plain></SENT>
<SENT sid="6" pm="."><plain>12.9%) after 43 months </plain></SENT>
<SENT sid="7" pm="."><plain>For the whole course of the disease, the relative risk (RR) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 357 (95% CI: 43-1290), as two overt <z:hpo ids='HP_0001909'>leukemias</z:hpo> were observed vs 0.0056 expected cases of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In the present cohort the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> although high, did not differ from our previous experience in patients treated conventionally for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and did not differ for patients receiving stem cells isolated from the bone marrow as compared to patients receiving stem cells isolated from peripheral blood </plain></SENT>
<SENT sid="9" pm="."><plain>Antecedent chemotherapy seems to be the critical factor for the development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> rather than the BEAM and ASCT regimen, which however may accelerate the evolution of the disease </plain></SENT>
</text></document>